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ABSTRACT Sporadic Creutzfeldt-Jakob disease (sCJD) cases are currently classified
according to the methionine/valine polymorphism at codon 129 of the PRNP gene
and the proteinase K-digested abnormal prion protein (PrPres) isoform identified by
Western blotting (type 1 or type 2). Converging evidence led to the view that MM/
MV1, VV/MV2, and VV1 and MM2 sCJD cases are caused by distinct prion strains.
However, in a significant proportion of sCJD patients, both type 1 and type 2 PrPres
were reported to accumulate in the brain, which raised questions about the diversity
of sCJD prion strains and the coexistence of two prion strains in the same pa-
tient. In this study, a panel of sCJD brain isolates (n  29) that displayed either a
single or mixed type 1/type 2 PrPres were transmitted into human-PrP-expressing
mice (tgHu). These bioassays demonstrated that two distinct prion strains (M1CJD
and V2CJD) were associated with the development of sCJD in MM1/MV1 and VV2/
MV2 patients. However, in about 35% of the investigated VV and MV cases,
transmission results were consistent with the presence of both M1CJD and V2CJD
strains, including in patients who displayed a “pure” type 1 or type 2 PrPres. The
use of a highly sensitive prion in vitro amplification technique that specifically
probes the V2CJD strain revealed the presence of the V2CJD prion in more than
80% of the investigated isolates, including isolates that propagated as a pure
M1CJD strain in tgHu. These results demonstrate that at least two sCJD prion
strains can be present in a single patient.
IMPORTANCE sCJD occurrence is currently assumed to result from spontaneous and
stochastic formation of a misfolded PrP nucleus in the brains of affected patients.
This original nucleus then recruits and converts nascent PrPC into PrPSc, leading to
the propagation of prions in the patient’s brain. Our study demonstrates the coexis-
tence of two prion strains in the brains of a majority of the 23 sCJD patients investi-
gated. The relative proportion of these sCJD strains varied both between patients
and between brain areas in a single patient. These findings strongly support the
view that the replication of an sCJD prion strain in the brain of a patient can result
in the propagation of different prion strain subpopulations. Beyond its conceptual
importance for our understanding of prion strain properties and evolution, the sCJD
strain mixture phenomenon and its frequency among patients have important impli-
cations for the development of therapeutic strategies for prion diseases.
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Transmissible spongiform encephalopathies (TSEs), otherwise known as prion dis-eases, are neurodegenerative disorders affecting a large spectrum of mammalian
species that share similar characteristics, including a long incubation period in acquired
forms (which in humans may be measured in decades) and a progressive clinical course
resulting in death (1). A key event in the pathogenesis of TSEs is the conversion of the
normal cellular prion protein (PrPC, which is encoded by the PRNP gene) into an
abnormal disease-associated isoform (PrPSc) in the tissues of infected individuals. PrPC
is completely degraded after controlled digestion with proteinase K (PK) in the pres-
ence of nondenaturing detergents. In contrast, PrPSc is N-terminally truncated under
such conditions, resulting in a PK-resistant core termed PrPres (2).
The most common form of human TSE is an idiopathic disorder named sporadic
Creutzfeldt-Jakob disease (sCJD). In sCJD, two major PrPres isoforms have been de-
scribed by Western blot (WB) analysis: in type 1 PrPres, the apparent molecular weight
of the unglycosylated fragment is 21 kDa, while in type 2, it is 19 kDa (3). In sCJD
patients, the polymorphism at codon 129 of the prion protein gene (methionine
[M]/valine [V]) and the PrPres type (type 1/type 2) are major determinants of the clinical
and neuropathological phenotypes of the disease (3, 4).
The currently identified clinical and neuropathological subtypes of sCJD mainly
result from codon 129 genotype/PrPTSE type combinations (MM1, VV1, MM2, and VV2),
with some exceptions. MM1 and MV1 cases are phenotypically indistinguishable and
therefore merged in a single subtype, MM/MV1. VV2 and VV1 constitute two pheno-
typically distinct subgroups. MV2 cases can be split into three categories according to
the predominant presence of cortical lesions (MV2C), presence of kuru type amyloid
plaques (MV2K), or a cooccurrence of these features (MV2KC) (5). Similarly, the MM2
group is divided into two subtypes based on the very distinctive cortical and thalamic
histopathology observed in the two groups (MM2-cortical or MM2C and MM2-thalamic
or MM2T). Finally, a variant of the MM1 subtype characterized by the presence of
widespread PrP amyloid plaques in the white matter has been recognized and desig-
nated p-MM1 (6). Based on these observations, it was proposed that the different sCJD
phenotype observed in patients (sCJD subtypes) could be associated with the propa-
gation of different sCJD agents (strains) in patients.
In past decades, the poor transmissibility of sCJD brain isolates to conventional
mouse models precluded the characterization of sCJD prion biological diversity. This
problem was the consequence of the transmission barrier phenomenon that naturally
limits the propagation of prions between hosts with different PrPC amino acid se-
quences (7). Mice genetically engineered to express human PrP (tgHu) in the absence
of endogenous mouse PrPC now allow the propagation of human CJD prions without
an apparent transmission barrier (8–11).
The main previous study on the characterization of prion strain diversity in sCJD
consisted of the transmission of a panel of six sCJD isolates in tgHu mice expressing the
Met129 or Val129 human PrP variant at physiological levels (knock-in mice) (12). The
bioassay results from the study of Bishop et al. (12) were consistent with the existence
of four distinct sCJD prion strains that corresponded to MM/MV type 1, MM type 2
(cortical), MV/VV type 2 and VV type 1 isolates. These data further supported the
contention that the combination of the dimorphism at codon 129 of the human PRNP
gene and the PrPres WB pattern (type 1 or type 2) in the brain tissues of patients
provides valuable indications on the nature of prion strains responsible for the disease
(12). However, in up to 35% of sCJD patients, both type 1 and type 2 PrPres can be
observed in either the same or different brain areas (13, 14). These observations raised
questions concerning the actual diversity of sCJD strains and/or the potential coexis-
tence of two or more prion strains in sCJD patients.
In the study presented here, a panel of brain homogenates from 23 sCJD cases
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originating in three different countries (France, United Kingdom [UK], and Spain) was
transmitted to mice that expressed methionine 129 and/or valine 129 human PrP (15).
These inocula included samples from individuals that were MM, MV, and VV with
respect to the human PrP genotype and displayed either a pure type 1 or type 2 PrPres
profile or both type 1 and type 2 PrPres types in their brain. These bioassays demon-
strated that two distinct prion strains, named here as M1CJD and V2CJD, were prefer-
entially associated with the development of sCJD in MM1/MV1 and VV2/MV2 patients,
respectively. However, in more than 50% of the investigated cases, bioassay and/or
prion in vitro protein misfolding cyclic amplification (PMCA) revealed the presence of
both M1CJD and V2CJD prion strains in the sCJD isolates. These results demonstrate that
multiple sCJD prion strains can propagate in a single patient. The existence and the
frequency of strain mixture phenomenon question the concepts that are currently used
to explain the spontaneous occurrence of prions in human sCJD.
RESULTS
Twenty-three sCJD cases were selected on the basis of their PrPres Western blot (WB)
profile and their genotype at codon 129 of the PRNP gene. The selected cases
originated from three different countries (France, Spain, and UK) and corresponded to
MM1, MV1, VV2, and MV2 sCJD cases, which together account for more than 95% of the
sCJD cases reported each year by surveillance systems in Europe (5). For each case, the
neuropathological data were reviewed to determine the potential particularities in their
neuropathological profile. This review indicated that all three identified subtypes of
MV2 cases (C, K, and CK) were part of the panel of isolates examined here (Table 1)
Among the selected cases, the first subset (cases 1 to 20) displayed a single PrPres
Western blot signature (type 1 or type 2) in the five different brain areas tested. A single
brain area (frontal cortex) from each of these cases was used in transmission experi-
ments (Table 1). The second subset (cases 21 to 23) corresponded to sCJD cases that
showed mixed type 1/type 2 PrPres signatures in either the same brain area or a
different brain area. Three brain areas from each of these cases were selected for
bioassay (see Table 3).
The 29 resulting isolates were transmitted (two iterative passages) to mice homozy-
gous for either methionine (tgMet) or valine (tgVal) at codon 129 of human PrP and to
their F1 cross (tgMet/Val). All of these different tgHu PrP mouse lines have been shown
to express approximately 4-fold-more PrPC in their brain than human brain tissue (15).
Identification of two dominant distinct sCJD strains. All the MM1sCJD isolates
(n  5) and 3 out of 5 MV1 sCJD isolates displayed a short incubation period in tgMet
mice (about 200 days postinoculation [dpi]), an intermediate incubation period in
tgMet/Val mice (about 250 dpi), and a longer one in tgVal mice (about 300 dpi)
(Table 1). Irrespective of the inoculated mouse line, a type 1 PrPres was observed in the
brains of the inoculated animals (Table 1 and Fig. 1). We named this transmission
pattern M1CJD.
The transmission of 5 out of 6 investigated VV2 isolates and 2 out of 4 MV2 isolates
was associated with a short incubation period in tgVal mice (about 180 dpi) and a long
incubation period in tgMet and tgMet/Val mice (480 to 600 dpi). The inoculated tgMet
and tgMet/Val mice accumulated a type 1 PrPres in their brain, while type 2 PrPres was
observed in tgVal brains (Fig. 1). This transmission pattern clearly differed from M1CJD
and was named V2CJD.
In affected tgMet, tgMet/Val, and tgVal mice, a vacuolar lesion profile (see Fig. 3) was
established by histological examination of the brain. In each of the three mouse lines,
the isolates that displayed an M1CJD transmission pattern showed similar lesion profiles
(Fig. 1). Similarly, all isolates displaying a V2 transmission pattern showed the same
lesion profile in the tgMet, tgMet/Val, and tgVal mouse lines (Fig. 1). However, the
lesion profile associated with the M1 isolates clearly differed from the profile associated
with the V2 isolates. Collectively, these results strongly supported the contention that
two different prion strains were responsible for the M1 and V2 transmission pattern.
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FIG 1 PrPres Western blot profiles (top) and vacuolar lesion profiles (bottom) in the brains of mice expressing human PrP inoculated with sporadic CJD (sCJD).
y score indicates intensity of vacuolar lesions; x axis indicates standard brain gray areas (1 to 9) and white areas (1 to 3). Transgenic mice that express the Met129
(tgMet), Val129 (tgVal) human PrP and their crossbreed (tgMet/Val) were inoculated intracerebrally (6 mice, 20 l per mouse) with a 10% brain homogenate
(frontal cortex) from sCJD cases that were Met129 (MM) homozygotes, Val129 (VV) homozygotes, or Met/VAl129 (MV) heterozygotes and displayed either a pure
type 1 or a pure type 2 PK-resistant PrP (PrPres) Western blot (WB) isoform (Table 1). Two iterative passages were performed for each line (Table 1). After
the second passage and in each mouse line, the isoform (type 1/type 2) of the PrPres was determined in the mouse brain by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and WB with the anti-PrP monoclonal antibody Sha31 (epitope YEDRYYRE). A PrPres type 1 isoform (MM1 sCJD
isolate) and type 2 isoform (VV2 sCJD isolate) were included as controls on each gel. The WB results obtained in each line are reported in Table 1. In parallel,
standardized vacuolar lesion profiles were established in the brains of the same mice. Symbols: in the MM1 lesion profile graphs, p, case 1; o, case 2; Œ, case
3; , case 4; e, case 5; in the MV1 lesion profile graphs, o, case 12; Œ, case 13; e, case 14; in the VV2 lesion profile graphs, p, case 6; o, case 7; Œ, case 8;
, case 9; e, case 10; in the MV2 lesion profile graphs, Œ, case 17; e, case 18.
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To confirm this, prions that propagated in tgMet and tgVal mice inoculated with
sCJD isolates 1, 6, 12, and 20 (2nd passage) were reinoculated in tgVal and tgMet mice,
respectively. The transmission patterns (incubation periods and PrPres Western blot
type [Table 2]) and the brain vacuolar lesion profiles that were observed in tgMet and
tgVal mice were identical to those obtained when the original isolates were inoculated
in the same mouse lines (Fig. 2). These results demonstrated that the M1CJD and V2CJD
transmission patterns in tgMet and tgVal mice were specific for two distinct and
apparently stable sCJD prion strains.
Discrepant transmission profile. The transmission in tgHu mice of 5 out of 20
isolates that correspond to patients who displayed a single PrPres Western blot signa-
ture in their brain (Table 1) resulted in a phenotype that differed from M1CJD and V2CJD.
This “discrepant” transmission pattern was observed in some of the VV2 (case 11), MV2
(cases 15 and 16), and MV1 (cases 19 and 20) isolates. It was characterized by a short
incubation period in tgMet mice (about 200 dpi), an intermediate incubation period in
tgMet/Val mice (about 250 dpi), and a short incubation period in tgVal mice (about
180 dpi) (Table 1). A type 1 PrPres accumulated in the brains of tgMet and tg Met/Val
mice, while type 2 PrPres was observed in tgVal mice (Fig. 3). In these discrepant
isolates, the vacuolar lesion profiles in the tgMet and tgMet/Val mice matched the
profiles observed in mice inoculated with the M1CJD strain, while in the tgVal mice, the
profile matched the profile for mice inoculated with the V2CJD strain (Fig. 3).
Strikingly, inoculation of the 9 isolates that corresponded to the three sCJD patients
who displayed a mixed type 1/type 2 PrPres Western blot profile resulted in two distinct
phenotypes (incubation period, PrPres Western blot pattern, and vacuolar lesion profile).
Seven of these isolates displayed a phenotype identical to those observed for the
discrepant isolates, while two others (cases 21 and 23, cerebellum) displayed a V2 strain
phenotype (Table 3 and Fig. 4).
These observations led us to consider the hypothesis that the discrepant phenotype
might result from the presence of both M1 and V2 strains in the isolates.
Artificial M1/V2 mixtures reproduce the discrepant phenotype. In order to test
our discrepant phenotype hypothesis, artificial M1CJD/V2CJD strain mixtures were cre-
ated. M1CJD and V2CJD strains were obtained by biological cloning (endpoint titration)
of an MM1 isolate (case 1) and a VV2 isolate (case 6) in tgMet and tgVal mice,
respectively (see Table S1 in the supplemental material). Strain mixtures were prepared
as 1/10 dilution series of a reference M1CJD strain stock homogenate (10% tgMet brain
TABLE 2 Transmission of sporadic CJD isolates adapted (two iterative passages) in mice












1 MM 1 2nd pass tgMet 6/6 202  11 1 6/6 298  9 1
2nd pass tgVal 6/6 212  5 1 6/6 276  5 1
12 MV 1 2nd pass tgMet 6/6 197  3 1 6/6 286  3 1
2nd pass tgVal 6/6 214  9 1 6/6 270  8 1
6 VV 2 2nd pass tgMet 5/5 508  22 6/6 182  7 2
2nd pass tgVal 6/6 498  34 1 6/6 171  3 2
20 MV 2 2nd pass tgMet 6/6 483  44 1 6/6 181  4 2
2nd pass tgVal 5/5 503  27 1 6/6 169  7 2
aFour sCJD cases displaying different PRNP genotypes at codon 129 (MM, homozygous Met129; VV,
homozygous Val129; MV, heterozygous Met/Val129) and PrPres Western blot isoform (type 1 or type 2) were
selected. The prions obtained after two passages (2nd pass) of these isolates in transgenic mice that
express the Met129 (tgMet) or Val129 (tgVal) human PrP were reinoculated (third passage) into tgVal and
tgMet (5 or 6 mice; 20 l per mouse). Brains from second passage mice were pooled and used as inoculum
for the third passage. The PrPres WB isoforms (type 1 or type 2) identified in mouse brains are reported.
bD/I, number of diseased mice/number of inoculated mice.
cIncubP, incubation period (time to death in days) shown as means  standard deviations.
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homogenate) in a reference V2CJD strain stock homogenate (10% tgVal brain homog-
enate) or vice versa. These artificial strain mixtures were then inoculated (two iterative
passages) into tgMet and tgVal mice (Table 4).
In tgVal mice, the V2 strain phenotype (160 to 180 dpi, type 2 PrPres Western blot
profile) was observed, after the first and/or second passage, in mice that received
M1CJD/V2CJD strain mixtures containing more than 103 diluted V2CJD strain. Below this
level, the M1CJD strain phenotype was observed in tgVal mice. In tgMet mice, the M1CJD
strain phenotype (190 to 210 dpi, type 1 PrPres Western blot profile) was recovered after
the first and/or second passage in mice that received strain mixtures more than a 104
diluted M1CJD strain. Below this level, the V2CJD strain phenotype was observed in the
inoculated tgMet mice.
FIG 2 Vacuolar lesion profiles in the brains of human-PrP-expressing mice (tgHu) inoculated with tgHu-adapted
sCJD isolates. Transgenic mice that express the Met129 (tgMet), Val129 (tgVal) human PrP were inoculated
intracerebrally (6 mice, 20 l per mouse) with a 10% brain homogenate (frontal cortex) from one MM1 sCJD patient
(case 1), one MV1 sCJD patient (case 12), one VV2 sCJD patient (case 6), and one MV2 sCJD patient (case 17). Two
iterative passages were performed for each line (Table 2). For each original sCJD isolate, the prions that were
obtained after the two passages in tgMet and tgVal were transmitted (third passage) in both tgMet and tgVal.
Graphs present the standardized vacuolar lesion profiles in the brains of the mice inoculated with the original sCJD
isolates (●) and the prions obtained after the second passage in tgMet (o) and tgVal (p).
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These results demonstrate that the discrepant phenotype observed when transmit-
ting certain sCJD isolates in tgMet and tgVal mice can be recreated by in vitro mixing
M1CJD/V2CJD strains. The data also indicate that the presence of a relatively low level of
M1CJD and V2CJD prion strains in isolates dominated by the V2CJD and M1CJD strains,
respectively, is sufficient to result in a discrepant transmission phenotype in tgHu mice.
M1CJD/V2CJD strain mixture in sCJD patients. In order to provide direct evidence
for the existence of M1CJD/V2CJD strain mixtures in the brains of sCJD patients, we
established a protein misfolding cyclic amplification (PMCA) protocol that specifically
identifies the seeding activity of the V2CJD prion strain. PMCA is a methodology that
mimics prion replication in vitro, but in an accelerated form, allowing amplification of
minute amounts of PrPSc and prion infectivity (16). In PMCA, a PrPC-containing “sub-
strate” is combined with a “seed” that may contain otherwise undetectable amounts of
PrPSc. After repeated cycles of incubation and sonication, the amount of PrPSc increases
to levels where they can be detected by conventional biochemical methods.
Biologically cloned M1CJD and V2CJD prion strains were obtained by endpoint
titration of sCJD isolates in tgMet and tgVal mice (Table S1). PMCA reactions that were
seeded with V2CJD cloned prions passaged in tgMet or tgVal mice were positive and
displayed a type 2 PrPres Western blot profile. Conversely, reactions seeded with M1CJD
cloned prions passaged in tgMet or tgVal mice were PrPres negative on Western blot
(Fig. 5a). This indicated that the PMCA protocol was able to selectively amplify the V2CJD
strain, but not the M1CJD strain.
To determine the sensitivity of V2CJD detection by this PMCA, the reference V2CJD
strain material that had previously undergone endpoint titration in tgVal mice (intra-
cerebral [i.c.] inoculation route) (Table S2) was retitrated by PMCA (Fig. 5b). The
amplification of a 10-fold serial dilution of this sample (6 individual replicates per
FIG 3 PrPres Western blot profiles and vacuolar lesion profiles in the brains of human PrP-expressing mice (tgHu) inoculated with discrepant phenotype sCJD
cases. VV2 (case 11 [o]), MV1 (case 15 [p] and case 16 [e]) and MV2 (case 19 [Œ] and case 20 []) sCJD isolates were inoculated into transgenic mice that
express Met129 (tgMet), Val129 (tgVal) human PrP and their crossbreed (tgMet/Val) (intracerebral route, 6 mice, 20 l per mouse). After two iterative passages
in tgMet, tgVal, and tgMet/Val mice, the PrPres WB profile was established in the mouse brains by SDS-PAGE and WB with the anti-PrP monoclonal antibody
Sha31 (epitope YEDRYYRE). A PrPres type 1 isoform (MM1 sCJD isolate [case 1]) and type 2 isoform (VV2 sCJD isolate [case 2]) were included as controls on each
gel. In parallel, standardized vacuolar lesion profiles in the brains of the mice that were inoculated with each isolate were established. Lesion profiles
corresponding to M1CJD (Œ) and V2CJD (●) strains are presented for comparison.
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dilution point) demonstrated that three PMCA rounds (24 h per round, i.e., 72 h) were
sufficient to reach the maximal sensitivity level of the assay. Additional PMCA rounds
improved neither the analytical sensitivity of the assay nor the number of positive
replicates (Fig. 5b). Importantly, the presence of the M1CJD strain did not affect the
sensitivity of V2CJD strain detection (Fig. 5c).
Based on these results, the seeding activity (SA) of the isolate was estimated by the
Spearman-Kärber method to be 109.3 50% SA (SA50) per ml of 10% brain homogenate.
The bioassay endpoint titration data of the same sample in tgVal mice gave an
infectious titer of 105.53 50% lethal dose (LD50) per ml of tissue homogenate (Table S2).
Taking into account the 4-fold-lower amount of material used to seed the PMCA
reaction compared to the material used in mouse inoculations, these results indicate
that the PMCA protocol we used was 1,500 times more sensitive than the bioassay in
tgVal mice for the detection of V2CJD prions.
Finally, the presence/level of V2CJD prion seeding activity in sCJD isolates originally
characterized by bioassay in tgHu mice was assessed by PMCA. A 1/10 dilution series
of the samples originally used to inoculate mice was prepared and used to seed PMCA
reactions (6 PMCA reactions per dilution). After three PMCA amplification rounds,
FIG 4 Vacuolar lesion profiles in the brains of human PrP-expressing mice (tgHu) inoculated with sCJD cases displaying mixed type 1/type 2 PrPres
WB profiles. Different brain area samples collected from VV (case 21) and MV (cases 22 and 23) sCJD patients displaying both type 1 and type
2 PrPres WB profile in their brain were inoculated (two iterative passages) in transgenic mice that express Met129 (tgMet) or Val129 (tgVal) human
PrP and their crossbreed (tgMet/Val) (intracerebral route, 6 mice, 20 l per mouse). After two passages, standardized vacuolar lesion profiles in
the brains of the mice inoculated with the caudate nucleus (Œ), cerebellum (o), temporal cortex (p), or occipital cortex (e) from the different
sCJD cases were established. Lesion profiles corresponding to M1CJD (Œ) and V2CJD (●) strains in the same tgHu lines are presented for comparison.
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reaction products were tested for the presence of PrPres by Western blotting (Fig. 6),
and prion seeding activity titers were estimated using the Spearman-Kärber method, or,
when appropriate, Poisson’s probabilistic model (Table 5).
A high seeding activity (107 SA50/ml) was observed in all the sCJD isolates that
displayed a V2CJD profile in bioassay. Moderate (103.6 SA50/ml) to very high (108
SA50/ml) seeding activity were observed in the isolates that displayed a discrepant
transmission phenotype in tgHu mice. Unexpectedly, low but consistent V2CJD seeding
activity were also observed in 3 out 4 MM1 sCJD isolates that displayed a pure M1CJD
transmission profile in tgHu mice. However, the seeding activity titers in these partic-
ular isolates were largely below the 103.8 SA50/ml that corresponded to the estimated
detection limit of the V2 CJD prion by bioassay in tgVal mice (Table 5). PrPres-positive
reactions all displayed a Western blot profile that was similar to the profile of the
original V2CJD prion strain.
DISCUSSION
The transmission of sCJD (from 23 sCJD cases) to mice that overexpress the
methionine and/or valine 129 variants of human PrPC allowed the identification of two
dominant sCJD strains, named M1CJD and V2CJD, which were preferentially associated
with MM/MV1 and MV/VV2 prion disease cases, respectively. These results confirm and
expand the observations reported by Bishop et al. on the basis of the inoculation
of a limited number of sCJD isolates in knock-in mice that expressed methionine
and/or valine 129 human PrP variants (12). Our results are also in agreement with
transmission results obtained more recently by other groups using Met129 human
PrP-overexpressing mice (17–19).
Fifteen years ago, the detection by Western blotting of both type 1 and type 2 PrPres
in the brains of a significant number of sCJD patients led to the proposal that more than














V2 neat M1 neat 6/6 207  3 1 6/6 205  2 1 6/6 173  7 2 6/6 179  1 2
V2 neat 6/6 549  65 1 6/6 506  17 1 6/6 175  5 2 6/6 174  3 2
M1 neat 6/6 210  12 1 6/6 199  3 1 6/6 295  5 1 6/6 283  11 1
V2 neat M1 101 6/6 244  11 1 6/6 203  8 1 6/6 177  6 2 ND
M1 102 6/6 250  5 1 6/6 198  3 1 6/6 171  6 2 ND
M1 103 6/6 329  89 1 6/6 207  5 1 6/6 173  10 2 ND
M1 104 6/6 463  67 1 6/6 201  7 1 6/6 176  10 2 ND
M1 10-5 6/6 513  32 1 6/6 505  24 1 6/6 176  5 2 ND
M1 neat V2 10-1 6/6 207  10 1 ND 6/6 190  8 2 6/6 179  3 2
V2 10-2 6/6 211  9 1 ND 6/6 233  13 2 6/6 189  8 2
V2 10-3 6/6 199  9 1 ND 6/6 245  2 2 6/6 189  8 2




M1 neat V2 10-5 6/6 202  8 1 ND 6/6 283  8 1 6/6 289  5 1
aM1CJD and V2CJD strains were obtained by the endpoint titration of an MM1 (case 1) and VV2 (case 6) sCJD isolate in Met129 (tgMet) or Val129 (tgVal) human PrP-
expressing mice, respectively (see Table S1 in the supplemental material). Brains from tgMet (inoculated with M1CJD strain) and tgVal (inoculated with V2CJD strain)
were used to produce stock solutions (10% tissue homogenates). A dilution series (1/10 dilution series) (in phosphate-buffered saline) of each stock solution was
prepared. M1CJD/V2CJD strain mixtures were obtained by mixing an equal volume of each component at the chosen dilutions. Samples were then transmitted (two
iterative passages) to tgMet and tgVal mice (intracerebral route, 20 l per mouse). Brains from first-passage-positive mice (PrPres presence in the brain) were pooled
and used for the second passage. The PrPres WB isoforms (type 1 or type 2) identified in mouse brains are reported.
bD/I, number of diseased mice/number of inoculated mice. ND, not done.
cIncubP, incubation period (time to death [in days]). The incubation periods are shown as means  standard deviations.
dThe asterisk indicates that the PrPres WB profile of the mice in this group were not homogenous, and the individual incubation period of each animal is presented.
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FIG 5 Amplification of M1CJD and V2CJD strains by protein misfolding cyclic amplification (PMCA). (a) PMCA reactions were seeded with brain
homogenate from methionine 129 (tgMet) and valine 129 (tgVal) mice inoculated (1st and 2nd passage) with M1CJD and V2CJD prion strains (102
dilution of a 10% brain homogenate). The PMCA substrate was prepared using tgVal brains. Unseeded reactions were included as specificity
controls. PMCA reactions were then subjected to 6 rounds of amplification, each comprising 96 cycles (10-s sonication for 14 min and 50-s
incubation at 39.5°C) in a Qsonica700. After each PMCA round, reaction products (1 volume) were mixed with fresh substrate (9 volumes) to seed
(Continued on next page)
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a single prion strain might be present in these individuals (13, 14). The results of our
study presented here definitively demonstrate the existence of M1CJD and V2CJD sCJD
prion strain mixtures in MV and VV cases that display both type 1 and type 2 PrPres by
Western blotting. However, our study also revealed that M1CJD/V2CJD strain mixtures
occur in a large proportion of the MM/MV1 and VV/MV2 sCJD cases (more than 40% of
the isolates in our panel), including those patients where neither the neuropathological
phenotype nor the PrPres Western blot profile suggested its existence.
The copropagation of two prion strains in the brains of sCJD patients and the
apparently frequent occurrence of this phenomenon naturally lead to the question of
its origin. In the absence of identifiable external sources that might explain sCJD
occurrence, it is currently assumed that this disease is triggered by the spontaneous
and stochastic formation of a misfolded PrP nucleus in the brain of the affected
individual. This original nucleus is considered to recruit and convert nascent PrPC into
PrPSc, leading to the progressive spread and propagation of prions in the brain of the
diseased patient (20).
Based on the postulate that the conformation of PrPSc molecules/aggregates en-
codes prion strain information (21, 22), several mechanisms could explain the cooccur-
rence of both M1CJD and V2CJD strains in MM/MV1 and MM/VV2 sCJD patients. First, the
two prion strains might arise concomitantly during the event(s) responsible for the
generation of the initial PrPSc nucleus. Since M1CJD and V2CJD display different capac-
FIG 5 Legend (Continued)
the following round. After six PMCA rounds, the products were analyzed by Western blotting (WB) for the presence of abnormal PK-resistant PrP
(PrPres antibody Sha31 epitope YEDRYYRE). A type 1 (MM1 [case 1]) and type 2 (VV2 [case 6]) PrPres controls were included as control on each
WB gel. (b) PMCA reactions were seeded with 10-fold serial dilutions of an V2CJD strain (tgVal 10% brain homogenate, 103 to 108 dilution in
PMCA buffer). Six rounds of amplification were performed. After each round, a part of the product was analyzed by WB for the presence of PrPres.
(c) PMCA reactions were seeded with 10-fold serial dilutions of a V2CJD strain (tgVal 10% brain homogenate, 103 to 108 dilution) in an M1CJD
strain (101 dilution of a 10% tgMet brain homogenate).
FIG 6 Specific probing of the V2CJD strain in sCJD isolates by protein misfolding cyclic amplification. PMCA reactions were seeded with a 1/10 dilution series
(101 to 108 dilutions of 10% brain homogenate in PMCA buffer) corresponding to different sCJD patients and/or different brain areas from a single patient
(Tables 1 and 3). PMCA reactions were subjected to 3 rounds of amplification, each comprising 96 cycles (10-s sonication for 14 min and 50-s incubation at
39.5°C) in a Qsonica700. This PMCA protocol allows amplification of the V2CJD strain, but not the M1CJD strain (Fig. 5). After three PMCA rounds, products were
analyzed by Western blotting (WB) for the presence of abnormal PK-resistant PrP (PrPres antibody Sha31 epitope YEDRYYRE). A type 1 (case 1) and type 2 (case
6) PrPres were included as controls on each WB gel. For each sample, the WB shows only PrPres presence/absence at dilutions bracketing the endpoint dilutions
(Table 5).
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ities to replicate in mice that express either Met129 or Val129 human PrP (see Table S1
in the supplemental material), the relative proportion of M1CJD and V2CJD prion strains
in the brains of affected individuals might be expected to vary according to their PRNP
codon 129 genotype. Alternatively, the occurrence of M1CJD/V2CJD prion mixtures in
sCJD patients could result from the nonclonal replication of prions as proposed by the
conformational selection hypothesis (21). This concept proposes that a prion strain
naturally propagates in its host as an ensemble of PrPSc conformers. The ensemble is
considered to be dominated by a major PrPSc conformer that preferentially propagates
in the host and is responsible for the observable prion strain phenotype. However,
other prion substrains, those associated with minor populations of PrPSc conformers,
are also proposed to be present and emerge as the dominant strain upon transmission
to a different host (21, 23). Differences in PrPC posttranslational modifications, metab-
olism, or expression levels have been shown in vitro and in vivo to impact the capacity
and efficacy of prion strain propagation (24). Variations both within and between
different brain areas could exert a selection pressure on the different prion substrains
generated or selected during the replication process (25–27). In such a scenario, the
combination of host PRNP codon 129 genotype with the temporal and topographical
region of the brain area(s) where the divergence of the prion strains could occur would











type Brain areab 101 102 103 104 105 106 107 108
1 MM 1 Front Cort M1 4/6 0/6 0/6 102.34
2 Front Cort M1 2/6 0/6 0/6 101.91
3 Front Cort M1 0/6 0/6 0/6
4 Front Cort M1 1/6 0/6 0/6 101.56
6 VV 2 Front Cort V2 6/6 6/6 6/6 6/6 6/6 6/6 4/6 0/6 109.47
8 Front Cort V2 6/6 6/6 6/6 6/6 3/6 0/6 0/6 0/6 107.3
11 Front Cort M1V2 6/6 6/6 6/6 6/6 5/6 2/6 0/6 0/6 107.97
12 MV 1 Front Cort M1 0/6 0/6 0/6 0/6
13 Front Cort M1 0/6 0/6 0/6 0/6
14 Front Cort M1 0/6 0/6 0/6 0/6
15 Front Cort M1V2 6/6 6/6 3/6 0/6 0/6 0/6 104.3
16 Front Cort M1V2 6/6 6/6 4/6 1/6 0/6 0/6 104.63
17 MV 2 Front Cort V2 6/6 6/6 6/6 6/6 4/6 1/6 0/6 0/6 107.63
20 Front Cort M1V2 6/6 6/6 6/6 6/6 6/6 5/6 1/6 0/6 108.8
21 VV 1 Caudate M1V2 6/6 6/6 6/6 6/6 6/6 4/6 0/6 0/6 108.47
2 Cerebellum V2 6/6 6/6 6/6 6/6 6/6 5/6 3/6 0/6 109.13
2 Temp. Cort M1V2 6/6 6/6 6/6 6/6 4/6 1/6 0/6 0/6 107.63
22 MV 2 Caudate V2 6/6 6/6 6/6 6/6 6/6 5/6 1/6 0/6 108.8
12 Cerebellum M1V2 6/6 6/6 6/6 6/6 6/6 3/6 2/6 0/6 108.63
2 Occip. Cort M1V2 6/6 6/6 6/6 6/6 6/6 2/6 0/6 0/6 108.13
23 MV 12 Caudate M1V2 6/6 6/6 4/6 2/6 0/6 0/6 104.8
2 Cerebellum V2 6/6 6/6 3/6 0/6 0/6 0/6 104.3
1 Temp. Cort M1V2 6/6 4/6 1/6 0/6 0/6 0/6 103.63
aPMCA reactions were seeded with a 1/10 dilution series of isolates (101 to 108 dilutions of 10% brain homogenate) corresponding to different sCJD affected
patients and/or different brain areas from the same patient (see Tables 1 and 3). The sample aliquots used to prepare dilution series were identical to those used for
transmission experiments in mice (Tables 1 and 3). For each sample and each dilution, six individual PMCA reactions were seeded. The PMCA protocol allows
amplifying the V2CJD strain, but not the M1CJD strain (Fig. 5). After three PMCA rounds, products were analyzed by Western blotting (WB) for the presence of
abnormal PK-resistant PrP (PrPres antibody Sha31 epitope YEDRYYRE). The number of PrPres WB-positive replicates corresponding to each round and each dilution are
reported.
bAbbreviations: Front Cort, frontal cortex; Caudate, caudate nucleus; Temp. Cort, temporal cortex; Occip. Cort, occipital cortex.
cValues for which one or more mice of the six mice tested showed V2 strain PMCA amplication are shown in boldface type.
dSeeding activity titers were estimated using Spearman Karber’s limiting dilution titration method (most likely value) or (when less than 100% positive reaction was
observed in the first tested dilution) by the Poisson’s probabilistic model as described by Brown et al. (51). Titers are given as the number of PMCA 50% seeding
activity (SA50) per milliliter of 10% brain homogenate.
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determine the final levels of M1CJD and V2CJD prion strains observed in specific brain
areas of each patient.
Our study here has investigated a substantial number of sCJD isolates (n  29),
which is significantly greater than previous studies aimed at describing the diversity of
sCJD prion strains (12, 17–19).
As a consequence, the data we have generated have been instrumental in demon-
strating the occurrence of the M1CJD/V2CJD strain mixture phenomenon in the MM/MV1
and MV/VV2 sCJD patients. Since our study was focused mainly on the existence of
multiple prion strains in specific subgroups of sCJD isolates, we have not been able to
fully address the total repertoire of prion strain diversity associated with this particular
human prion disease. However, our data indicate that MV2C and MV2K cases (Table 1),
which were proposed to be caused by different sCJD strains on the basis of clinical and
neuropathological features in patients (5), could be due to the same prion strain. These
findings suggest that the same prions could be associated with different forms of prion
disease in humans that share the same PRNP genotype at codon 129. Alternatively, it
could signify that bioassay of these isolates in tgHu mice was unable to reflect their true
prion strain diversity.
To date, the existence of a total of five distinct sCJD prion strains have been formally
established by bioassay in tgHu mice. In addition to the M1CJD and V2CJD strains
identified here, the existence of M2CJD and V1CJD strains was established on the basis
of the absence of transmission in knock-in human PrP mice of one MM2C case and one
VV1 sCJD case, respectively (12). MM2C was later shown to be transmissible to mice that
overexpress human PrP (17). An additional prion strain was identified on the basis of
the transmission of one MM2 thalamic case in Met129 human PrP mice (28). Considering
the relative variability in terms of prion strain content that we observed within the
MM/MV1 and VV/MV2 isolates assessed here, it is difficult to reconcile that strain typing
by bioassay of a single isolate could provide a reliable reflection of the diversity of
prions associated with a particular sCJD clinicopathological phenotype. Moreover, at
this time, there is a lack of comprehensive bioassay-based strain typing data for certain
clinicopathological subtypes of sCJD, such as the MM2 thalamic forms or MM1 and
MM2 cases (5). If mixtures of prion strains other than M1CJD/V2CJD exist in sCJD cases,
the final characterization of their diversity in this form of human prion disease could be
very challenging.
The occurrence and frequency of the sCJD strain mixture phenomenon in sCJD
patients will have important implications for the development of therapeutic strategies
for prion diseases. The efforts deployed over the last 20 years to identify chemical or
biological interventions that would be able to slow or revert the progression of sCJD
have remained elusive. The hurdles to surmount the development of therapy against
sCJD are numerous (e.g., early diagnosis of CJD in patients, blood-brain barrier pas-
sage). The existence of the strain mixture phenomenon reported here could represent
an additional difficulty. Indeed, it has been clearly established in different animal and
cellular models of prion disease that the efficacy of antiprion compounds can vary
significantly according to the prion strain under investigation (23, 29–32). Accordingly,
in the context of multiple prion strains within individual sCJD patients, only treatments
that are effective against the full spectrum of prion strains are likely to provide a
therapeutic benefit.
The results reported in this study demonstrate that two prion strains can be present
in the brain of individual sCJD patients. The transmission of variant CJD (vCJD) isolates
to human PrP mice was reported to lead to the propagation of either vCJD or sCJD-like
prion, suggesting that two prion strains might have been present in the original isolates
(33). The coexistence of at least two prion strains in the brain of the same individual was
also reported for small ruminants with scrapie, cattle with atypical H-type bovine
spongiform encephalopathy (BSE-H) (the presence of minor classical BSE component),
and in cervids with chronic wasting disease (34–37). This supports the view that strain
mixture occurrence might be a relatively common phenomenon across mammal prion
diseases.
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The presence in a single individual of two prion strains, including components that
remain undetected by standard examination of the isolates, has important conse-
quences for public health. The interactions between the prion strain and host features
(mainly defined by the PrPC sequence) determine the distribution and levels of infec-
tivity in the tissues and body fluids of incubating and clinically affected individuals.
Moreover, the capacity of a prion to transmit between hosts from different species also
depends on the nature of the prion strain (transmission barrier phenomenon) (7). In
animals used for human food, the presence of several prion substrains could result in
an unrecognized exposure of consumers to minor populations of prions displaying a
zoonotic potential.
In humans, iatrogenic transmission has been responsible for the occurrence of
several hundreds of CJD cases. These cases have mainly occurred in recipients of
human pituitary-derived growth hormone (GH) or human dura mater (DM) grafts (38).
The strain mixture phenomenon in patients either incubating or affected by CJD is
unlikely to have a major impact on the risks of iatrogenic transmission in exposed
patients. However, the coexistence of two or more sCJD strains in donors from whom
DM grafts or GH extracts were prepared might have influenced the phenotypic and
epidemiological diversity of these iatrogenic cohorts (39–41).
MATERIALS AND METHODS
Ethics statement. All animal experiments were performed in compliance with institutional and
French national guidelines in accordance with the European Union directives 86/609/EEC and 2010/63/
EU. Experiments were approved by the Committee on the Ethics of Animal Experiments of the authors’
institutions: INRA Toulouse/ENVT (permit number 01734.01) and Instituto Nacional de Investigación y
Tecnología Agraria y Alimentaria (INIA) (permit number CEAA 2011/046).
Concerning the human sCJD samples, in all cases, informed consent for research was obtained, and
the material used had appropriate ethical approval for use in this project.
In France, human brain samples were obtained from the Brain Bank of CHU of Toulouse (approval
number AC62009-973/20-01-2010). Samples were pseudoanonymized before dispatch.
In the United Kingdom (UK), human brain samples were obtained from the National CJD Research &
Surveillance Unit Brain and Tissue Bank in Edinburgh, UK, which is part of the MRC Edinburgh Brain Bank.
For the purposes of this study, samples were pseudoanonymized using a Brain Bank reference number.
All UK cases had informed consent for research, and their supply and use in this study were covered by
Ethics Approval (LREC 2000/4/157: National Creutzfeldt-Jakob disease tissue bank: acquisition and use of
autopsy material for research on human transmissible spongiform encephalopathies, James Ironside,
amended date 9 October 2007).
In Spain, human brain samples were obtained from the Basque Biobank of the Basque Foundation
for Health Innovation and Research, Vizcaya, Spain. Samples were anonymized using a Brain Bank
reference number. All Spanish cases had informed consent for research, and their supply and use in this
study were covered by Ethics Approval of the Euskadi Clinical Research Ethics Committee (CEIC-E
02/2012).
sCJD cases. Twenty-three cases of sCJD, each of which had frozen tissue (2 to 4 g) available from 5
brain regions: (occipital, temporal, and frontal cortex, cerebellum, and the caudate nucleus), were
included in this study. The patients originated from France, UK, and Spain.
The four major subtypes of sCJD patients (MM1, MV1, MV2, and VV2) were represented in our panel
(Table 1 and Table 3). None of the patients had a familial history of prion disease, and in each case, the
entire PRNP coding sequence was analyzed (42, 43).
Tissue homogenate preparation. Frozen brain tissue (175  20 mg) was homogenized in 5%
glucose in distilled water in grinding tubes (Bio-Rad) adjusted to 10% (wt/vol) using a TeSeE Precess 48
homogenizer (Bio-Rad).
Transgenic mouse lines. tg340 and tg361 mouse lines that express human PrP methionine at codon
129 or valine at codon 129, respectively, in a PrPKo (Ko stands for knockout) background, were generated
as previously described (10, 15). Both tg340 (tgMet) and tg361 (tgVal) are homozygous for the human
PRNP gene, and tgMet/Val129 mice used in our experiments were obtained by mating tg340 and tg361
mice (F1 generation).
Mouse bioassays. Six- to ten-week-old female mice were anesthetized and inoculated with 2 g of
brain equivalent (20 l of a 10% temporal cortex homogenate) in the right parietal lobe using a 25-gauge
disposable hypodermic needle.
Mice were observed daily, and their neurological status was assessed weekly by qualified veterinar-
ians. Three signs of neurological dysfunction (any three signs of the following signs: tremor, ataxia,
difficulty righting from supine position, rigidity of tail, kyphosis, paralysis of the lower limbs, or
bradykinesia) were required to give a mouse a positive score for TSE clinical signs (44).
When clinically progressive TSE disease was evident, the animals were euthanized, and their brains
were harvested. Half of the brain from those animals that had displayed TSE clinical signs was fixed by
immersion in 10% Formol saline, and the other half was frozen at –20°C. Tissues from mice found dead
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were frozen (no formalin fixation). The incubation period was expressed as the mean survival time (time
to death) (in days postinoculation [dpi]), with its corresponding standard deviation, for the euthanized
mice and the mice found dead that were scored positive for both TSE clinical signs and brain PrPres. In
animals where no clinical signs were observed, mice were killed at the end of their natural life span (750
to 800 days). In cages where no animal developed clinical TSE signs, incubation periods are reported in
the table as 650 or 750 dpi.
Abnormal PrP Western blot detection. Proteinase K (PK)-resistant abnormal PrP extraction (PrPres)
and Western blotting (WB) were performed as previously described (45). Immunodetection was per-
formed using the monoclonal PrP-specific antibody Sha31 (1 g/ml), which recognize the amino acid
sequence YEDRYYRE (positions 145 to 152) (46).
Vacuolar lesion profiles. Hematoxylin-eosin-stained paraffin-embedded brain tissue sections were
used to establish standardized vacuolar lesion profiles in mice as previously described (47, 48). Each
lesion profile was based on data obtained from 5 or 6 animals.
Prion strain biological cloning and endpoint titration. Successive 1/10 dilutions of 10% brain
homogenate (frontal cortex) from a MM1 sCJD patient (case 1) and a VV2 sCJD patient (case 6) were
inoculated intracerebrally into tgMet mice (n  6) and tgVal mice (n  6). These data have been
presented in a previous study (49). The brains of the last PrPSc-positive MM1 in tgMet mice and VV2 in
tgVal mice (in the highest dilution groups) were used to reinoculate groups of tgMet mice (n  12) and
tgVal mice (n  12). The brains of these tgMet and tgVal animals were pooled to constitute two reference
material stocks (named M1CJD and V2CJD). The V2CJD stock homogenate was endpoint titrated by bioassay
in tgVal mice (inoculation of successive 1/10 dilutions of 10% homogenates [see Table S2 in the
supplemental material]). The V2CJD infectious titer was estimated by the Spearman-Kärber method (50).
PMCA reactions and prion seeding activity titers. Brains from tgVal mice were used to prepare the
PMCA substrate as previously described (11). PMCA amplification was performed as previously described
(45). Each PMCA run included a reference sCJD sample (V2CJD stock homogenate titrated in tgVal mice)
as a control for the amplification efficiency. Unseeded controls (1 unseeded control for 8 seeded
reactions) were also included in each run. Each dilution of each sample was tested (six replicates) in two
independent runs. For each sample, the number of positive replicates (presence of detectable PrPres in
the reaction as assessed by WB) is reported. The titer of prion seeding activity (50% seeding activity [SA50]
per milliliter of homogenate) was estimated by the Spearman-Kärber method (50) or (when less than
100% of the PMCA reactions seeded with the first dilution were found positive) by the limiting dilution
titration method (application of Poisson’s probabilistic model) described by Brown et al. (51).
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
TABLE S1, DOCX file, 0.02 MB.
TABLE S2, DOCX file, 0.02 MB.
ACKNOWLEDGMENTS
This work was funded by the European Regional Development Fund POCTEFA
TRANSPRION (EFA282/13) and REDPRION (EFA148/16), by the UK Food Standards
Agency exploring permeability of the species (M03043 and FS231051), by the European
Union through FP7 222887 “Priority,” the Alliance Biosecure Foundation (FABS201403),
and the Spanish Ministerio de Economía y Competitividad (AGL2016-78054-R [AEI/
FEDER, UE]). A.M.-M. was supported by a fellowship from the INIA (FPI-SGIT-2015-02).
We are greatly indebted to R. Bujdoso (Cambridge University) for his critical reading
of our manuscript.
REFERENCES
1. Fraser H. 1976. The pathology of a natural and experimental scrapie.
Front Biol 44:267–305.
2. McKinley MP, Bolton DC, Prusiner SB. 1983. A protease-resistant protein
is a structural component of the scrapie prion. Cell 35:57– 62. https://
doi.org/10.1016/0092-8674(83)90207-6.
3. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M,
Dickson DW, Sima AA, Trojanowski JQ, Petersen RB, Gambetti P. 1996.
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob dis-
ease. Ann Neurol 39:767–778. https://doi.org/10.1002/ana.410390613.
4. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr
I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N,
Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H. 1999. Classification
of sporadic Creutzfeldt-Jakob disease based on molecular and pheno-
typic analysis of 300 subjects. Ann Neurol 46:224 –233. https://doi.org/
10.1002/1531-8249(199908)46:2224::AID-ANA123.0.CO;2-W.
5. Zerr I, Parchi P. 2018. Sporadic Creutzfeldt-Jakob disease. Handb Clin Neurol
153:155–174. https://doi.org/10.1016/B978-0-444-63945-5.00009-X.
6. Kobayashi A, Arima K, Ogawa M, Murata M, Fukuda T, Kitamoto T. 2008.
Plaque-type deposition of prion protein in the damaged white matter of
sporadic Creutzfeldt-Jakob disease MM1 patients. Acta Neuropathol
116:561–566. https://doi.org/10.1007/s00401-008-0425-8.
7. Beringue V, Vilotte JL, Laude H. 2008. Prion agent diversity and species
barrier. Vet Res 39:47. https://doi.org/10.1051/vetres:2008024.
8. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, Doey LJ,
Lantos P. 1997. The same prion strain causes vCJD and BSE. Nature
389:448 – 450, 526. https://doi.org/10.1038/38925.
9. Asante EA, Linehan JM, Desbruslais M, Joiner S, Gowland I, Wood AL,
Welch J, Hill AF, Lloyd SE, Wadsworth JD, Collinge J. 2002. BSE prions
propagate as either variant CJD-like or sporadic CJD-like prion strains
in transgenic mice expressing human prion protein. EMBO J 21:
6358 – 6366. https://doi.org/10.1093/emboj/cdf653.
10. Padilla D, Beringue V, Espinosa JC, Andreoletti O, Jaumain E, Reine F,
Herzog L, Gutierrez-Adan A, Pintado B, Laude H, Torres JM. 2011. Sheep
and goat BSE propagate more efficiently than cattle BSE in human
Two Prion Strains Can Coexist in sCJD Patients ®
May/June 2020 Volume 11 Issue 3 e00393-20 mbio.asm.org 17
 on A








PrP transgenic mice. PLoS Pathog 7:e1001319. https://doi.org/10.1371/
journal.ppat.1001319.
11. Douet JY, Zafar S, Perret-Liaudet A, Lacroux C, Lugan S, Aron N, Cassard
H, Ponto C, Corbiere F, Torres JM, Zerr I, Andreoletti O. 2014. Detection
of infectivity in blood of persons with variant and sporadic Creutzfeldt-
Jakob disease. Emerg Infect Dis 20:114 –117. https://doi.org/10.3201/
eid2001.130353.
12. Bishop MT, Will RG, Manson JC. 2010. Defining sporadic Creutzfeldt-
Jakob disease strains and their transmission properties. Proc Natl Acad
Sci U S A 107:12005–12010. https://doi.org/10.1073/pnas.1004688107.
13. Uro-Coste E, Cassard H, Simon S, Lugan S, Bilheude J-M, Perret-Liaudet
A, Ironside JW, Haik S, Basset-Leobon C, Lacroux C, Peoch’ K, Streichen-
berger N, Langeveld J, Head MW, Grassi J, Hauw J-J, Schelcher F, Delisle
MB, Andréoletti O. 2008. Beyond PrP9res type 1/type 2 dichotomy in
Creutzfeldt-Jakob disease. PLoS Pathog 4:e1000029. https://doi.org/10
.1371/journal.ppat.1000029.
14. Polymenidou M, Stoeck K, Glatzel M, Vey M, Bellon A, Aguzzi A. 2005.
Coexistence of multiple PrPSc types in individuals with Creutzfeldt-
Jakob disease. Lancet Neurol 4:805– 814. https://doi.org/10.1016/S1474
-4422(05)70225-8.
15. Cassard H, Torres JM, Lacroux C, Douet JY, Benestad SL, Lantier F, Lugan
S, Lantier I, Costes P, Aron N, Reine F, Herzog L, Espinosa JC, Beringue V,
Andreoletti O. 2014. Evidence for zoonotic potential of ovine scrapie
prions. Nat Commun 5:5821. https://doi.org/10.1038/ncomms6821.
16. Saborio GP, Permanne B, Soto C. 2001. Sensitive detection of patholog-
ical prion protein by cyclic amplification of protein misfolding. Nature
411:810 – 813. https://doi.org/10.1038/35081095.
17. Chapuis J, Moudjou M, Reine F, Herzog L, Jaumain E, Chapuis C, Quadrio
I, Boulliat J, Perret-Liaudet A, Dron M, Laude H, Rezaei H, Béringue V.
2016. Emergence of two prion subtypes in ovine PrP transgenic mice
infected with human MM2-cortical Creutzfeldt-Jakob disease prions.
Acta Neuropathol Commun 4:10. https://doi.org/10.1186/s40478-016
-0284-9.
18. Jaumain E, Quadrio I, Herzog L, Reine F, Rezaei H, Andréoletti O, Laude
H, Perret-Liaudet A, Haïk S, Béringue V. 2016. Absence of evidence for a
causal link between bovine spongiform encephalopathy strain variant
L-BSE and known forms of sporadic Creutzfeldt-Jakob disease in human
PrP transgenic mice. J Virol 90:10867–10874. https://doi.org/10.1128/JVI
.01383-16.
19. Kobayashi A, Sakuma N, Matsuura Y, Mohri S, Aguzzi A, Kitamoto T. 2010.
Experimental verification of a traceback phenomenon in prion infection.
J Virol 84:3230 –3238. https://doi.org/10.1128/JVI.02387-09.
20. Colby DW, Prusiner SB. 2011. Prions. Cold Spring Harb Perspect Biol
3:a006833. https://doi.org/10.1101/cshperspect.a006833.
21. Collinge J, Clarke AR. 2007. A general model of prion strains and their
pathogenicity. Science 318:930 –936. https://doi.org/10.1126/science
.1138718.
22. Laferriere F, Tixador P, Moudjou M, Chapuis J, Sibille P, Herzog L, Reine
F, Jaumain E, Laude H, Rezaei H, Beringue V. 2013. Quaternary structure
of pathological prion protein as a determining factor of strain-specific
prion replication dynamics. PLoS Pathog 9:e1003702. https://doi.org/10
.1371/journal.ppat.1003702.
23. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. 2010. Dar-
winian evolution of prions in cell culture. Science 327:869 – 872. https://
doi.org/10.1126/science.1183218.
24. Le Dur A, Lai TL, Stinnakre MG, Laisne A, Chenais N, Rakotobe S, Passet
B, Reine F, Soulier S, Herzog L, Tilly G, Rezaei H, Beringue V, Vilotte JL,
Laude H. 2017. Divergent prion strain evolution driven by PrP(C) expres-
sion level in transgenic mice. Nat Commun 8:14170. https://doi.org/10
.1038/ncomms14170.
25. Beringue V, Mallinson G, Kaisar M, Tayebi M, Sattar Z, Jackson G, Anstee
D, Collinge J, Hawke S. 2003. Regional heterogeneity of cellular prion
protein isoforms in the mouse brain. Brain 126:2065–2073. https://doi
.org/10.1093/brain/awg205.
26. Ford MJ, Burton LJ, Morris RJ, Hall SM. 2002. Selective expression of prion
protein in peripheral tissues of the adult mouse. Neuroscience 113:
177–192. https://doi.org/10.1016/s0306-4522(02)00155-0.
27. Moya KL, Sales N, Hassig R, Creminon C, Grassi J, Di Giamberardino L.
2000. Immunolocalization of the cellular prion protein in normal
brain. Microsc Res Tech 50:58 – 65. https://doi.org/10.1002/1097-0029
(20000701)50:158::AID-JEMT93.0.CO;2-5.
28. Moda F, Suardi S, Di Fede G, Indaco A, Limido L, Vimercati C, Ruggerone
M, Campagnani I, Langeveld J, Terruzzi A, Brambilla A, Zerbi P, Fociani P,
Bishop MT, Will RG, Manson JC, Giaccone G, Tagliavini F. 2012. MM2-
thalamic Creutzfeldt-Jakob disease: neuropathological, biochemical and
transmission studies identify a distinctive prion strain. Brain Pathol
22:662– 669. https://doi.org/10.1111/j.1750-3639.2012.00572.x.
29. McKenzie D, Kaczkowski J, Marsh R, Aiken J. 1994. Amphotericin B delays
both scrapie agent replication and PrP-res accumulation early in infec-
tion. J Virol 68:7534 –7536. https://doi.org/10.1128/JVI.68.11.7534-7536
.1994.
30. Adjou KT, Demaimay R, Lasmezas CI, Seman M, Deslys JP, Dormont D.
1996. Differential effects of a new amphotericin B derivative, MS-8209,
on mouse BSE and scrapie: implications for the mechanism of action of
polyene antibiotics. Res Virol 147:213–218. https://doi.org/10.1016/0923
-2516(96)89651-8.
31. Kimberlin RH, Walker CA. 1983. The antiviral compound HPA-23 can
prevent scrapie when administered at the time of infection. Arch Virol
78:9 –18. https://doi.org/10.1007/BF01310854.
32. Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G, DeArmond SJ,
Prusiner SB. 2009. Continuous quinacrine treatment results in the for-
mation of drug-resistant prions. PLoS Pathog 5:e1000673. https://doi
.org/10.1371/journal.ppat.1000673.
33. Béringue V, Le Dur A, Tixador P, Reine F, Lepourry L, Perret-Liaudet A,
Haïk S, Vilotte J-L, Fontés M, Laude H. 2008. Prominent and persistent
extraneural infection in human PrP transgenic mice infected with variant
CJD. PLoS One 3:e1419. https://doi.org/10.1371/journal.pone.0001419.
34. Torres JM, Andreoletti O, Lacroux C, Prieto I, Lorenzo P, Larska M, Baron T,
Espinosa JC. 2011. Classical bovine spongiform encephalopathy by trans-
mission of H-type prion in homologous prion protein context. Emerg Infect
Dis 17:1636–1644. https://doi.org/10.3201/eid1709.101403.
35. Thackray AM, Hopkins L, Lockey R, Spiropoulos J, Bujdoso R. 2011.
Emergence of multiple prion strains from single isolates of ovine scrapie.
J Gen Virol 92:1482–1491. https://doi.org/10.1099/vir.0.028886-0.
36. Angers RC, Kang HE, Napier D, Browning S, Seward T, Mathiason C,
Balachandran A, McKenzie D, Castilla J, Soto C, Jewell J, Graham C,
Hoover EA, Telling GC. 2010. Prion strain mutation determined by prion
protein conformational compatibility and primary structure. Science
328:1154 –1158. https://doi.org/10.1126/science.1187107.
37. Mazza M, Iulini B, Vaccari G, Acutis PL, Martucci F, Esposito E, Peletto S,
Barocci S, Chiappini B, Corona C, Barbieri I, Caramelli M, Agrimi U,
Casalone C, Nonno R. 2010. Co-existence of classical scrapie and Nor98
in a sheep from an Italian outbreak. Res Vet Sci 88:478 – 485. https://doi
.org/10.1016/j.rvsc.2009.11.015.
38. Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, Will RG,
Ladogana A, Pocchiari M, Leschek EW, Schonberger LB. 2012. Iatro-
genic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 18:
901–907. https://doi.org/10.3201/eid1806.120116.
39. Ritchie DL, Barria MA, Peden AH, Yull HM, Kirkpatrick J, Adlard P, Ironside
JW, Head MW. 2017. UK iatrogenic Creutzfeldt-Jakob disease: investigat-
ing human prion transmission across genotypic barriers using human
tissue-based and molecular approaches. Acta Neuropathol 133:579 –595.
https://doi.org/10.1007/s00401-016-1638-x.
40. Brandel JP, Preece M, Brown P, Croes E, Laplanche JL, Agid Y, Will R,
Alperovitch A. 2003. Distribution of codon 129 genotype in human
growth hormone-treated CJD patients in France and the UK. Lancet
362:128 –130. https://doi.org/10.1016/S0140-6736(03)13867-6.
41. Rudge P, Jaunmuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J,
Norsworthy P, Hummerich H, Druyeh R, Wadsworth JD, Brandner S,
Hyare H, Mead S, Collinge J. 2015. Iatrogenic CJD due to pituitary-
derived growth hormone with genetically determined incubation times
of up to 40 years. Brain 138:3386 –3399. https://doi.org/10.1093/brain/
awv235.
42. Moreno CR, Moazami-Goudarzi K, Laurent P, Cazeau G, Andreoletti O,
Chadi S, Elsen JM, Calavas D. 2007. Which PrP haplotypes in a French
sheep population are the most susceptible to atypical scrapie? Arch Virol
152:1229 –1232. https://doi.org/10.1007/s00705-007-0956-7.
43. Andreoletti O, Levavasseur E, Uro-Coste E, Tabouret G, Sarradin P, Delisle
MB, Berthon P, Salvayre R, Schelcher F, Negre-Salvayre A. 2002. Astro-
cytes accumulate 4-hydroxynonenal adducts in murine scrapie and
human Creutzfeldt-Jakob disease. Neurobiol Dis 11:386 –393. https://doi
.org/10.1006/nbdi.2002.0558.
44. Outram GW. 1976. The pathogenesis of scrapie in mice. Front Biol
44:325–357.
45. Lacroux C, Comoy E, Moudjou M, Perret-Liaudet A, Lugan S, Litaise C,
Simmons H, Jas-Duval C, Lantier I, Béringue V, Groschup M, Fichet G,
Costes P, Streichenberger N, Lantier F, Deslys JP, Vilette D, Andréoletti O.
Cassard et al. ®
May/June 2020 Volume 11 Issue 3 e00393-20 mbio.asm.org 18
 on A








2014. Preclinical detection of variant CJD and BSE prions in blood. PLoS
Pathog 10:e1004202. https://doi.org/10.1371/journal.ppat.1004202.
46. Feraudet C, Morel N, Simon S, Volland H, Frobert Y, Creminon C,
Vilette D, Lehmann S, Grassi J. 2005. Screening of 145 anti-PrP
monoclonal antibodies for their capacity to inhibit PrPSc replication
in infected cells. J Biol Chem 280:11247–11258. https://doi.org/10
.1074/jbc.M407006200.
47. Fraser H, Dickinson AG. 1968. The sequential development of the brain
lesion of scrapie in three strains of mice. J Comp Pathol 78:301–311.
https://doi.org/10.1016/0021-9975(68)90006-6.
48. Fraser H, Dickinson AG. 1973. Scrapie in mice. Agent-strain differences in
the distribution and intensity of grey matter vacuolation. J Comp Pathol
83:29 – 40. https://doi.org/10.1016/0021-9975(73)90024-8.
49. Huor A, Douet JY, Lacroux C, Lugan S, Tillier C, Aron N, Cassard H, Arnold
M, Torres JM, Ironside JW, Andreoletti O. 2017. Infectivity in bone
marrow from sporadic CJD patients. J Pathol 243:273–278. https://doi
.org/10.1002/path.4954.
50. Markus RA, Frank J, Groshen S, Azen SP. 1995. An alternative approach
to the optimal design of an LD50 bioassay. Stat Med 14:841– 852.
https://doi.org/10.1002/sim.4780140812.
51. Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R, Drohan
WN. 1999. Further studies of blood infectivity in an experimental model
of transmissible spongiform encephalopathy, with an explanation of
why blood components do not transmit Creutzfeldt-Jakob disease in
humans. Transfusion 39:1169 –1178. https://doi.org/10.1046/j.1537-2995
.1999.39111169.x.
Two Prion Strains Can Coexist in sCJD Patients ®
May/June 2020 Volume 11 Issue 3 e00393-20 mbio.asm.org 19
 on A
pril 13, 2021 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
